ISVD Polypeptides Block vWF-Platelet Aggregation in TTP

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for Thrombotic Thrombocytopenic Purpura (TTP) are invasive, require multiple plasma exchanges and transfusions, and carry significant risks of complications and mortality, with no direct pharmacological targeting of the active process of ULvWF-mediated platelet aggregation.

Innovation Solution

Administration of polypeptides comprising at least one Immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) to human TTP patients, which specifically binds to vWF, blocking its interaction with platelet receptor GPIb-IX-V, thereby reducing pathological platelet aggregation and thrombosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If plasma exchange and transfusion are used to treat TTP, then ADAMTS13 is replaced and antibodies are removed, but the treatment requires multiple exchanges and transfusions over many days with no direct pharmacological targeting of ULvWF-mediated platelet aggregation

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential function of blocking ULvWF-mediated platelet aggregation by using a monoclonal antibody (caplacizumab) that specifically targets the A1 domain of vWF, separating this specific blocking function from the complex plasma exchange process

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The monoclonal antibody acts as an intermediary substance that binds to ULvWF and prevents its interaction with platelet GPIb-IX-V receptors, mediating the blocking of platelet aggregation without requiring direct plasma exchange

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If plasma exchange and transfusion are used to treat TTP, then ADAMTS13 is replaced, but the treatment requires multiple exchanges and transfusions over many days

Engineering Contradiction:

ImproveADAMTS13 replacementVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The monoclonal antibody provides immediate preliminary blocking of ULvWF-mediated platelet aggregation from the first dose, eliminating the need to wait for multiple plasma exchanges to achieve therapeutic effect

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The monoclonal antibody maintains continuous blocking of ULvWF-mediated platelet aggregation throughout the treatment period, providing sustained therapeutic action without the intermittent nature of multiple plasma exchanges

Inventive Principle:

Principle #20Continuity of useful action

3Reliability

If plasma exchange and transfusion are used to treat TTP, then antibodies against ADAMTS13 are removed, but there is no direct pharmacological targeting of the active process of ULvWF-mediated platelet aggregation

Engineering Contradiction:

Improveantibody removalVSAvoidpharmacological targeting

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The monoclonal antibody provides localized specific blocking at the vWF-A1 domain/GPIb-IX-V receptor interaction interface, concentrating the therapeutic effect directly at the site of platelet aggregation rather than relying on non-specific plasma exchange

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The administration of these polypeptides significantly reduces the time-to-response by accelerating platelet recovery, decreases the number of exacerbations, reduces hospitalization and morbidity, and lowers mortality, while also reducing the need for plasma exchanges and transfusions, with a favorable safety profile.

Implementation Method 1

polypeptides comprising at least one Immunoglobulin single variable domain (ISVD) against vWF... specifically binds to vWF, blocking its interaction with platelet receptor GPIb-IX-V

Methodology Applied

Scientific EffectAntibody binding:

Data Source

PatentUS12269893B2Methods of treating TTP with immunoglobulin single variable domains and uses thereof

Publication Date: 2025.04.08 ABLYNX NV

AI summary

The present invention is based on the finding that administration of polypeptides comprising at least one immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.